inPractice® - Antivirals

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/3/19 (What's New)

Multiple interactions have been described between HCV DAAs and antiretrovirals (Table 12); thus, the concomitant treatment of both HCV and HIV must be planned carefully with consideration of these interactions
- Management guidelines provide specific guidance on the use of HCV DAAs with ARV agents^{[DHHS ART; AASLD/IDSA HCV]}
- HCV DAAs also have multiple important interactions with other agents that are commonly used by HIV-infected patients; prescribing information should be checked carefully before initiating either agent^{[DHHS ART; FDA Simeprevir; FDA Ledipasvir/Sofosbuvir; FDA Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir; FDA Sofosbuvir/Velpatasvir; FDA Elbasvir/Grazoprevir; FDA Daclatasvir; FDA Sofosbuvir; FDA Glecaprevir/Pibrentasvir; FDA Sofosbuvir/Velpatasvir/Voxilaprevir; AASLD/IDSA HCV]}